CLINICOMICROBIOLOGICAL STUDY OF INFECTIONS CAUSED BY ACINETOBACTER SPECIES
Objectives: To study the rate of isolation of Acinetobacter species, its antibiogram and associated risk factors.
Methods: Retrospective time bound study for 6 months. The study included 191 consecutive clinical significant isolates of Acinetobacter species
isolated from various specimens. The identification and antibiotic susceptibility testing by modified Kirby Bauer and Vitek Compact system 2.
Results: Maximum isolation of Acinetobacter species was from suction tip (31.94%), sputum (19.89%), urine (14.66%), blood (10.47%), and others.
The species was most sensitive to colistin (97.87%) and polymyxin B (99.43%). The species was most resistant to imipenem (72.62%) and gentamicin
(66.66%). The common risk factors were invasive procedure, duration of intensive care unit stay, and malignancies.
Conclusion: Acinetobacter has emerged as a major nosocomial pathogen. Antibiotic resistance is on rise. Proper antibiotic stewardship is required
to curtail antibiotic resistance in this region.
Keywords: Acinetobacter spp., Antibiotic resistance, Health care associated pathogen
2. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: Emergence of a successful pathogen. Clin Microbiol Rev 2008;21(3):538-82.
3. Yu Yu, Yang Q, Xu XW, Kong HS, Xu GY, Zhong BY. Typing and characterization of carbapenems-resistant Acinetobacter calcoaceticus - Baumannii complex in a Chinese hospital. J Med Microbiol 2004;53:653â€‘6.
4. Sinha N, Agarwal J, Srivastava S, Singh M. Analysis of carbapenem-resistant Acinetobacter from a tertiary care setting in North India. Indian J Med Microbiol 2013;31(1):60-3.
5. Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, et al. Multidrug-resistant acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis. 2007;13:97-103.
6. Scott P, Deye G, Srinivasan A, Murray C, Moran K, Hulten E, et al. An outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus complex infection in the US military health care system associated with military operations in Iraq. Clin Infect Dis 2007;44(12):1577-84.
7. Mittal N, Nair D, Gupta N, Rawat D, Kabra S, Kumar S, et al. Outbreak of Acinetobacter spp septicemia in a neonatal ICU. Southeast Asian J Trop Med Public Health 2003;34(2):365-6.
8. Appleman MD, Belzberg H, Citron DM, Heseltine PN, Yellin AE, Murray J, et al. In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak. Antimicrob Agents Chemother 2000;44(4):1035-40.
9. Dash M, Padhi S, Pattnaik S, Mohanty I, Misra P. Frequency, risk factors, and antibiogram of Acinetobacter species isolated from various clinical samples in a tertiary care hospital in Odisha, India. Avicenna J Med 2013;3(4):97-102.
10. Tripathi PC, Gajbhiye SR, Agrawal GN. Clinical and antimicrobial profile of Acinetobacter spp: An emerging nosocomial superbug. Adv Biomed Res 2014;3:13.
11. Vaja D, Kavathia D, Goswami D, Chouhan D. A prevalence study of Acinetobacter species and their sensitivity pattern in a tertiary care hospital Rajkot City of Gujarat (India): A hospital based study. IOSR J Dent Med Sci 2016;15(7):54-8.
12. Mostofi S, Mirnejad R, Masjedian F. Multiâ€‘drug resistance in Acinetobacter baumannii strains isolated from clinical specimens from three hospitals in Tehranâ€‘Iran. Afr J Microbiol Res 2011;5(26):3579â€‘82.
13. Joshi SG, Litake GM, Satpute MG, Telang NV, Ghole VS, Niphadkar KB. Clinical and demographic features of infection caused by Acinetobacter species. Indian J Med Sci 2006;60(9):351-60.
14. Dent LL, Marshall DR, Pratap S, Hulette RB. Multidrug resistant Acinetobacter baumannii: A descriptive study in a city hospital. BMC Infect Dis 2010;10:196.
15. Lone R, Shah A, Kadri SM, Lone S, Faisal S. Nosocomial multiâ€‘drugâ€‘resistant Acinetobacter infections - Clinical findings, risk factors and demographic characteristics. Bangladesh J Med Microbiol 2009;3(1):34â€‘8.
Table 1: Rate of isolation of Acinetobacter spp. isolated from different clinical specimen
Specimen Number of isolates (%) Sputum 38 (19.89) Wound swab 19 (9.95) Suction tip 61 (31.94) Blood 20 (10.47) Urine 28 (14.66) Others 25 (13.09) Table 2: Antibiotic resistance pattern of Acinetobacter spp.
Antibiotics Number of resistant isolates (%) Amikacin 65 (69.89) Cefotaxim 66 (92.95) Ceftazidime 65 (87.83)
Ceftriaxone 112 (81.15) Ciprofloxacin 138 (73.79) Colistin 4 (2.12) Gentamicin 124 (66.66) Imipenem 130 (72.62) Meropenem 73 (76.84) Piperacillin/tazobactum 120 (69.36) Polymyxin B 0 (0) Tigecycline 13 (8.72)
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.